Form 4: Clover Health Insider Sells Shares Under 10b5-1 Plan

Clover Health Investments Corp. CEO Jamie L. Reynoso sold 2,360 shares of Class A Common Stock for $4.78 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp., sold 2,360 shares of Class A Common Stock on June 17, 2026.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on March 12, 2026.
• The reported price of $4.78 is a weighted average for sales ranging from $4.73 to $4.87 per share.
• Following the transaction, Reynoso beneficially owns 2,841,211 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction was conducted under a pre-planned Rule 10b5-1 trading plan, mitigating concerns about insider trading based on new information.

Negatives

• Insider selling can sometimes be perceived negatively by the market, although this sale was conducted under a pre-established trading plan.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a transaction by an insider.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common and are designed to allow executives to diversify their holdings or meet financial obligations without being perceived as trading on material non-public information. However, the volume and timing of such sales can still influence investor sentiment.

Stakeholder Impact

• Shareholders: The sale was executed under a pre-arranged plan, which is a standard practice to avoid insider trading concerns. However, any insider selling can be a point of observation for investors.

Key Dates

Keywords

Clover Health Investments, CLOV, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, CEO, Medicare Advantage